Patents Represented by Attorney Mei Hong
  • Patent number: 8236928
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: August 7, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Patent number: 8221983
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: July 17, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Vivien W. Chan, Jaime Escobedo, Pablo Dominguez Garcia, Rhonda Hansen, Joerg Kaufmann, Giulia C. Kennedy, George Lamson, Edward J. Moler, Filippo Randazzo, Christoph Reinhard, Julie Sudduth-Klinger
  • Patent number: 8173375
    Abstract: Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David Ying Chien, Yiu-Lian Fong, Azita Tabrizi, Heather Todd, Mark David VanCleve
  • Patent number: 8101349
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: January 24, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Pablo Dominguez Garcia, Altaf Kassam, George Lamson
  • Patent number: 7927839
    Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: April 19, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Venkatakrishna Shyamala
  • Patent number: 7834144
    Abstract: The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region and the carboxy-terminal region where the peptoid region comprises 3 to about 30 N-substituted glycines, and optionally one or more amino acids. The invention also relates to methods of using the peptoids in detecting and isolating prions, and in the treatment and prevention of prion-related diseases.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: November 16, 2010
    Assignee: Novartis AG
    Inventors: David Peretz, Michael D. Connolly, Ronald Zuckermann, Man Gao, Gulliver Timoteo, Robert M. Shimizu
  • Patent number: 7833758
    Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: November 16, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Venkatakrishna Shyamala
  • Patent number: 7807813
    Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: October 5, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Venkatakrishna Shyamala
  • Patent number: 7776523
    Abstract: Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 17, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Pablo D. Garcia, Stephen F. Hardy, Jaime Escobedo, Lewis T. Williams
  • Patent number: 7771730
    Abstract: Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: August 10, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Steve H. Nguyen, Sergio Pichuantes
  • Patent number: 7563873
    Abstract: Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: July 21, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David Ying Chien, Yiu-Lian Fong, Azita Tabrizi, Heather Todd, Mark David Van Cleve